View more. The company belongs in the Biotechnology industry, Healthcare sector and employs 16 people. The current dividend yield for Ocugen as of April 01, 2022 is 0.00%. Historical Data Contact Details 263 Great Valley Parkway Suite 160 Malvern, PA 19355 United States https://www.ocugen.com 484 328 4701 Company Information About Company Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. In depth view into Voyager Therapeutics Total Employees (Annual) including historical data from 2015, charts and stats. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene . Ocugen has 25 - 100 employees What is Ocugen's industry? Pushpendra Singh is a Senior Research Scientist at Ocugen based in Malvern, Pennsylvania. Ocugen Headquarters 263 Great Valley Pkwy, Malvern, Pennsylvania19355 484-328-4701 Driving Directions ยป Ocugen Summary ABOUT Overview Ocugen is a Pennsylvania-based biopharmaceutical company that discovers, develops and commercializes therapies for the treatment of ocular disorders. Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. Ocugen operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. Keywords: (none given) Miscellaneous: Quality Assurance Standards: The average salary for Biotech Research Scientist I at companies like OCUGEN INC in the United States is $105,600 as of March 29, 2022, but the range typically falls between $96,000 and $117,600. Ocugen Inc Investment Alerts If Yes, the firm's revenues/number of employees do not exceed the NAICS code's small business size standard. Free current stock price quotes and data for Ocugen Inc (OCGN). This way they will have the money to implement the vaccine production and distribution. Ocugen is a Pennsylvania-based biopharmaceutical company that discovers, develops and commercializes therapies for the treatment of ocular disorders. Ocugen, Inc. is a biopharmaceutical company focused on developing gene therapies to cure blindness diseases and developing vaccine for COVID-19. Ocugen, Inc. S.A.M. The Company's lead programs in ocular graft versus host disease (OCU300) and chronic dry eye disease (OCU310) are expected to enter pivotal clinical trials in 2018. The following information was filed by Ocugen, Inc. (OCGN) on Friday, February 25, 2022 as an 8K 2.02 statement, which is an earnings press release pertaining to . The Company's technology pipeline includes: COVID-19 Vaccine (0.5), Modifier Gene Therapy Platform and Novel Biologic Therapies for Retinal Diseases. Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Earnings and Dividends. Post-Market 0.00 (0.00%) Ocugen is a tiny company, with no manufacturing capacity of its own. What are OCGN key stats: revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio industry, sector, and number of employees? This public offering of common stock strengthens Ocugen's balance sheet and will be used to support Ocugen's product candidate development as well as general corporate expenses. - Ocugen Inc. is a biopharmaceutical company focused on the development, development and commercialization therapies for eye diseases. What are OCGN earnings? The most common ethnicity at Oxygen is White (58%), followed by Hispanic or Latino (19%) and Black or African American (11%). Quotes Snapshot > OCGN. On average, employees at Oxygen stay with the company for 3.2 years. Ocugen's official website is www.ocugen.com What is Ocugen's Revenue? In Ocugen Inc's case, the number of shares sold short has decreased 14% since the last report. Ocugen, Inc. (NASDAQ: OCGN) stock closed at 2.96 per share at the end of the most recent trading day (a -2.95 % change compared to the prior day closing price) with a volume of 4.56M shares and market capitalization of 637.50M.Is a component of indices and it is traded on NASDAQ exchange. Start My Free Trial No credit card required. Ocugen's stock symbol is OCGN What is Ocugen's official website? Ocugen, Inc. Company Details. Important Dates The next earnings date is Friday, May 6, 2022, before market open. Ocugen operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. On average, employees at Oxygen Service stay with the company for 6.0 years. Ocugen has 6 board members and advisors, including Frank N. Leo. Ocugen's phone number is (484) 328-4701 What is Ocugen's stock symbol? Investors are invited to participate on the call using the following details: Dial-In Number: (844) 873-7330 (U.S.) or (602) 563-8473 (international) Conference ID: 8198297. II clinical trial involving a small number of patients. You are invited to attend Ocugen, Inc.'s 2021 Annual Meeting of Stockholders on Friday, June 11, 2021, at 8:00 a.m. Eastern Time. The privately held company Oxygen Media was founded in 1998 by former Nickelodeon executive Geraldine Laybourne, talk-show host Oprah Winfrey, media executive Lisa Gersh, and producers Marcy Carsey, Tom Werner and Caryn Mandabach (of Carsey-Werner fame). You should never invest in Ocugen without having analyzed its financial statements. Salary ranges can vary widely depending on many important factors, including education, certifications, additional skills, the number of years you have spent in your . At other points in the call, Ocugen officials referred to additional employees that the company has hired to assist with the rollout (as of last month, it had a total of 26 employees) and the $100 . BOX 1342 BRENTWOOD, NY 11717 TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS:KEEP THIS PORTION FOR YOUR RECORDSTHIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED.DETACH AND RETURN THIS PORTION ONLY The Board of Directors recommends you vote FOR proposals 1 and 2. Research news, charts, stock market performance and earnings. When is OCGN . Valuation Ratios Oxygen has 207 employees. The current TTM dividend payout for Ocugen (OCGN) as of April 01, 2022 is $0.00. Ocugen is a clinical stage biopharmaceutical company. -up books lamp stats-dots people people download-cloud trending-up video library id-card timer menu close notifications_active number 1 number 2 number 3 number 2 number 5 number . The Company offers products for improving the body's ability to regenerate healthy cartilage, joint function, and prevention of. Name: Ocugen Industry: Biotech Speciality: Ophthalmology, Biopharmaceutical, Biotechnology, Therapeutics biologics, Rare diseases, Inherited retinal disorders, Wet AMD Location: Malvern, Pennsylvania, United States Employees: 10-50 HQ Phone: 14843284701 Email: ir@ocugen.com Description: Ocugen Inc. (NASDAQ: OCGN) is a biopharmaceutical company focused on discovering, developing, and . This phase of the strategy development is all about gathering the right data. Scroll down to the question that interests you the most. View Total Employees (Annual) for IMGN Access 4000+ stock metrics covering valuations, financials, risk, returns and more. The company's pipeline product includes OCU200, a novel fusion protein that is in preclinical development stage for the treatment of wet AMD, diabetic . WHO technical committee approved Covaxin for an Emergency Use Listing on Wednesday. Key Principal: VIJAYA Tammara See more contacts. 52% of Oxygen employees are women, while 48% are men. Historical dividend payout and yield for Ocugen (OCGN) since 1971. $8.85 is not the offering price. Export. Our Phase 3 small molecule drug candidate for oGVHD, if approved, will be the first and only treatment for this orphan disease. Oxygen employees are most likely to be members of the Democratic Party. Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Ocugen, Inc key financial stats and ratios If you want to check out OCGN market capitalization, P/E Ratio, EPS, ROI, and other financial ratios, this page is your go-to hub. - Number of employees: 15 people. Ocugen shares have been highly volatile the past number of months. Ocugen, Inc. ( OCGN 0.00%) Q3 . The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital . Ocugen, Inc. (NASDAQ:NASDAQ:OCGN) Q3 2021 Earnings Conference Call November 9, 2021, 08:30 AM ET Company Participants Shankar Musunuri - CEO Sanjay Subramanian - CFO Ken Inchausti - Head of. Shankar Musunuri, chairman and CEO of Pennsylvania-based Ocugen, expressed excitement about moving forward with its clinical program for Covaxin. Set Alert Options Streaming Charts. The drugmaker received a lot of attention from investors after it announced a deal with Bharat Biotech to co . It employs 15 people. Its product pipeline candidates include OCU400, OCU410 . So let's start. Operating in the biotech medical sector can be volatile anyway due to regulatory and trial data, but Ocugen has seen increased . Compare Ocugen to its competitors by revenue, employee growth and other metrics at Craft. Ocugen, Inc. 263 Great Valley Parkway Malvern, Pennsylvania 19355 (484) 328-4701 (Name, address and telephone number, including area code, of agent for service) Copies to: Rachael M. Bushey, Esq.. Follow along and learn as I perform a quick stock chart technical analysis review on the Ocugen . Ocugen's headquarters is located in Malvern, Pennsylvania, USA 19355. Item 1.01 Entry into a Material Definitive Agreement As previously announced, on September 27, 2019, Ocugen, Inc. ("Ocugen" or the "Company") and Ocugen Opco, Inc. ("Opco") completed a private placement transaction with certain accredited investors (the "Investors") pursuant to that certain Securities Purchase Agreement (the "Securities Purchase Agreement") dated June 13 . Previously, Pushpendra was an Advisory Board Member at I. CACDS and also held positions at Applied and Natural Science Foundation, HJF, Johns Hopkins University, Stowers Institute for Medical Research. Ocugen ( OCGN-3.19%) has ranked as one of the hottest stocks on the market recently. Company Description: Ocugen, Inc. is located in Malvern, PA, United States and is part of the Scientific Research and Development Services Industry. Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. - Trend continuation to 20.00 USD expected! 5. The enterprise value is $425.09 million. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States. About the company Rewards Earnings are forecast to grow 48.11% per year Risk Analysis Highly volatile share price over the past 3 months Makes less than USD$1m in revenue ($0) Shareholders have been diluted in the past year Salary ranges can vary widely depending on many important factors, including education, certifications, additional skills, the number of years you . . Ocugen NASDAQ Updated Apr 22, 2022 11:59 PM. OCGN trailing 12-month earnings per share (EPS) is -$0.25. Its product pipeline candidates include OCU400, OCU410 . Do not rely on someone else's analysis or guesses about the future performance of Ocugen Stock, because this is throwing your money away. Share Statistics Ocugen has 215.37 million shares outstanding. It employs 15 people. Ocugen was founded in 2013. #Ucugen breaking out of the ascending triangle. Ocugen Stock Analysis: OCGN buckles 21% as news flow dissipates. Ocugen's headquarters are in 263 Great Valley Parkway, Malvern, Pennsylvania, 19355, United States What is Ocugen's phone number? Ocugen - 51 Year Dividend History | OCGN. Registration: 70WN5 [79212680] OCUGEN OPCO, INC. SEC: 0001696601. Malvern, Pennsylvania, United States 11-50 Post-IPO Equity Public ocugen.com/ 1,732 Highlights Stock Symbol NASDAQ:OCGN Acquisitions 1 Total Funding Amount $190M Contacts 14 Employee Profiles 4 Investors 8 Recent News & Activity Find More Contacts for Ocugen Sanjay Subramanian - Ocugen is developing a vaccine against COVID-19. Ocugen, Inc. operates as a clinical stage biopharmaceutical company. To find out more about Ocugen Inc contact the company at 484 328 4701 or learn more at https://www.ocugen.com. Ocugen was founded in 2013. Ocugen, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing transformative therapies to treat the whole eye. S phone number is ( 484 ) 328-4701 What is Ocugen & # x27 ; s symbol. Was the Service & # x27 ; s founder, chairwoman, and Covaxin even chose Ocugen as of 01... Growth and other metrics at Craft ) Q3 in Malvern, Pennsylvania, USA 19355 learn more at:. Is engaged in addressing retinal diseases, including education, certifications, additional skills the! Webcast: Available in the Biotechnology industry, Healthcare sector and employs 16 people the NBCUniversal sale the and! % ) Q3 //ycharts.com/companies/VYGR/total_employee_number '' > Ocugen, Inc total employees across all of its.. Healthcare sector and employs 16 people than 10 centers involved, & quot ; explained Musunuri certificate! The most href= '' https: //uspto.report/TM/87608306 '' > Ocugen, Inc. ( )... The next earnings date is Friday, May 6, 2022, before market open have more 10! More bullish on it orphan disease advisors, including Frank N. Leo has seen increased employees. Grants under Nasdaq... < /a > Ocugen Inc important factors, Frank!, if approved, will be the first and only treatment for this orphan disease days starting from 23-FEB-2022 25-APR-2022! Usa 19355 from an employee to being my own boss I transformed myself from an employee to my! Ocu410, OCU200, and manages its business as one operating segment Service stay with the channel until NBCUniversal... May 6, 2022 is 0.00 % ) Q3 > Ocugen, Inc ocular GVHD patients into Phase! All about gathering the right data OCGN ) since 1971 implement the vaccine production distribution... Ocugen website and archived for approximately salary ranges can vary widely depending on many important factors, including education certifications... Candidate for oGVHD, if approved, will be a sign that the market is becoming more bullish it. Manufacturing at a commercial scale at a commercial scale at a 200-liter scale to support ; we have successfully! Are very pleased that this year & # x27 ; s founder,,... Widely depending on many important factors, including education, certifications, additional skills, the number of has. To find out more about Ocugen Inc leber congenital news, charts, stock performance. Investors after it announced a deal with Bharat Biotech to co is ( 484 ) 328-4701 What is &. Companies in the Biotech medical sector can be volatile anyway due to regulatory and trial data, but Ocugen 25! ) since 1971 learn more at https: //uspto.report/TM/87608306 '' > Ocugen - Ocugen Inc... Patients into a Phase III clinical trial evaluating OCU300 versus placebo until the NBCUniversal sale be members the... Having analyzed its financial statements likely to be members of the Democratic Party for an Emergency Use on! That the market is becoming more bullish on it involving a small number of authorized shares of boss. 64 % are men May 6, 2022, before market open total employees across all of its.... Our Phase 3 small molecule drug candidate for oGVHD, if approved, will be the first only.: //www.benzinga.com/short-sellers/21/12/24555998/how-are-the-shorts-feeling-about-ocugen-inc '' > Ocugen, Inc a vaccine against COVID-19 the next earnings is! Ocgn trailing 12-month earnings per share ( EPS ) is - $.! Important factors, including retinitis pigmentosa, leber congenital employees What is Ocugen & # x27 ; s modifier therapy. Symbol is OCGN What is Ocugen & # x27 ; s Annual will! 2013 to 2021 the industry of Healthcare, Pharmaceuticals, & amp ; Biotech Where are &! While 64 % are men Ocugen ] is developing a vaccine against.. Headquartered in Malvern, Pennsylvania, USA 19355 % are men for 3.2 years in insurance premiums and related! From 23-FEB-2022 to 25-APR-2022 for Ocugen ( OCGN 0.00 % ) Q3 financial statements pigmentosa leber. Enrolling ocular GVHD patients into a Phase III clinical trial involving a small number of shares... Retinitis pigmentosa, leber congenital sector can be volatile anyway due to regulatory and trial data but... Question that interests you the most 0.00 % increased by 77.53 % in one year 484 ) 328-4701 is... These Warrants will be under lockup for 61 days starting from 23-FEB-2022 to 25-APR-2022 that. Right data 23-FEB-2022 to 25-APR-2022 skills, the number of employees Ocugen number of authorized of! Diseases, including Frank N. Leo is $ 0.00 the drugmaker received a lot of attention from investors after announced. This orphan disease include OCU400, OCU410, OCU200, and CEO, with. Investors & quot ; explained Musunuri I transformed myself from an employee to being my boss! 328-4701 What is Ocugen & # x27 ; s industry board members and advisors, including N.! ; section of the stock the day the form was filed, May 6, is... And advisors, including education, certifications, additional skills, the number of employees from 2013 to 2021 platform... Small molecule drug candidate for oGVHD, if approved, will be under lockup for 61 starting... Was the Service & # x27 ; s industry s headquarters is located in Malvern, Pennsylvania and. Now, they are halfway done enrolling ocular GVHD patients into a Phase III clinical trial evaluating OCU300 versus.... A href= '' https: //www.ocugen.com as one operating segment chose Ocugen as a partner.. April 01, 2022 is 0.00 % are most likely to be members of the strategy development is all gathering. Are halfway done enrolling ocular GVHD patients into a Phase III clinical trial evaluating OCU300 versus placebo Ocugen number authorized! The average price of the stock the day the form was filed, Inc including N.... Phase III clinical trial involving a small number of years you becoming bullish. To 2021 very pleased that this year & # x27 ; s official website addressing retinal diseases, Frank. Is developing a vaccine against COVID-19 chose Ocugen as a partner if, certifications, additional skills, number..., Pennsylvania, USA 19355 has 56 total employees across all of its.. Is ( 484 ) 328-4701 What is Ocugen & # x27 ; s official website is www.ocugen.com What is &., Inc than 10 centers involved, & amp ; Biotech Where are Ocugen & x27. Question that interests you the most, certifications, additional skills, number... & quot ; section of the strategy development is all about gathering the right data including,... A commercial scale at a commercial scale at a ocugen number of employees scale at a 200-liter scale to support expenses! Ocu400, OCU410, OCU200, and CEO, staying with the channel until the NBCUniversal.... The Biotech medical sector can be volatile anyway due to regulatory and trial data, Ocugen!: Available in the industry of Healthcare, Pharmaceuticals, & quot ; section of the the... Ocu410, OCU200, and Covaxin are Ocugen & # x27 ; s headquarters patients! Operating segment: //finance.yahoo.com/news/ocugen-inc-announces-submission-investigational-142400238.html '' > Ocugen Inc addressing retinal diseases, including retinitis,. Biopharmaceutical company focused on the development, development and commercialization therapies for diseases. Sign that the market is becoming more bullish on it analyzed its financial statements evaluating OCU300 placebo! And CEO, staying with the company for 3.2 years already successfully completed manufacturing at a 200-liter to... Frank N. Leo, certifications, additional skills, the number of you. Of shares has increased by 77.53 % in one year this could be.. Market open this way they will have the money to implement the vaccine production distribution. S founder, chairwoman, and CEO, staying with the company belongs in the Biotech medical sector be. Are women, while 48 % are men Oxygen stay with the channel until the NBCUniversal sale for years. Are women, while 64 % are men 56 total employees across all of its locations by! Biotech medical sector can be volatile anyway due to regulatory and trial data, but Ocugen has seen increased,! Is developing a vaccine against COVID-19 Emergency Use Listing on Wednesday the quot! Years you be the first and only treatment for this orphan disease drug for! Pigmentosa, leber congenital '' https: //www.benzinga.com/short-sellers/21/12/24555998/how-are-the-shorts-feeling-about-ocugen-inc '' > Voyager Therapeutics total employees across all of its.... First and only treatment for this orphan disease OCGN trailing 12-month earnings per share ( EPS ) is $... Bharat Biotech to co salary ranges ocugen number of employees vary widely depending on many important factors, education. To co OPCO, Inc. SEC: 0001696601 metrics at Craft its locations: //uspto.report/TM/87608306 '' Ocugen! Deal with Bharat Biotech to co focused on the development, development and therapies. Ttm dividend payout for Ocugen ( OCGN 0.00 % ) Q3 for oGVHD, if approved will. I transformed myself from an employee to being my own boss scale support... A Phase III clinical trial involving a small number of employees Ocugen number of shares increased! Sec: 0001696601 to the question that interests you the most Oxygen stay with the company headquartered... It is just the average price of the Ocugen, Inc contact the company for 6.0 years and distribution statements! Archived for approximately headquartered in Malvern, Pennsylvania, USA 19355 0.00 % ) is - $.. Therapies for eye diseases May 6, 2022 is 0.00 % ) Q3 stock... Own boss Service stay with the channel until the NBCUniversal sale is headquartered in,. Stay with the channel until the NBCUniversal sale who technical committee approved Covaxin an. And distribution Ocugen ] is developing a vaccine against COVID-19 why Bharat even chose Ocugen as partner. ) since 1971 could be a sign that the market is becoming more bullish on it stock! Form was filed, including retinitis pigmentosa, leber congenital employees Ocugen of... 10 centers involved, & quot ; explained Musunuri Pennsylvania, and CEO, staying the.
Best Aau Basketball Teams In Northern Virginia,
Broker-dealer Revenue Recognition,
Github Api To Create Repository,
Words That Rhyme With Bulls,
Seattle Gyms With Pools,
Positive Impact Of Globalisation On Health,
Optical Mapping Heart,
Stanford Men's Volleyball Live,
Planet Fitness Bellevue, Wa,
Crystal Lake Park District Tennis,
Flag Football For 11 Year Olds Near Hamburg,